Vinpocetine: Brain Booster or Unapproved Drug? The FDA Ruling Explained

← Back to articles

Vinpocetine is a chemically modified version of vincamine, a compound from the lesser periwinkle plant (Vinca minor). It has been sold as a prescription drug for cognitive impairment in Hungary, Russia, and other Eastern European markets (under names like Cavinton) since the 1970s, and at the same time as an over-the-counter nootropic in the United States. In 2016 and again in 2019, the US FDA stated that vinpocetine does not legally qualify as a dietary ingredient and should not be sold as a supplement, especially because of risks during pregnancy. The product is still widely available, which leaves shoppers in a confusing regulatory gray zone.

The FDA position

Under the Dietary Supplement Health and Education Act (DSHEA, 1994), supplements may contain ingredients that were already on the market as foods or supplements before that date. Vinpocetine was first developed and sold as a pharmaceutical, not as a food. In 2016 the FDA published a tentative conclusion that vinpocetine never qualified as a dietary ingredient, and in November 2019 the agency confirmed that finding and warned women of childbearing age in particular not to use vinpocetine supplements (FDA, “FDA statement on warning for women of childbearing age about possible safety risks of dietary supplements containing vinpocetine,” June 2019). Enforcement has been uneven, and many products remain on store shelves.

Pregnancy: the serious concern

The FDA’s 2019 warning was driven by a National Toxicology Program / NIH review (NTP, 2019) of vinpocetine's reproductive toxicology. In pregnant rats and rabbits, vinpocetine at exposures comparable to typical human supplement doses caused fetal loss and reduced fetal weight. On that basis, FDA stated that vinpocetine should not be used by women who are pregnant or could become pregnant. Most consumer-facing labels do not display this warning prominently. Health Canada has also not approved vinpocetine as a Natural Health Product, and several products have been refused entry under the Natural and Non-prescription Health Products Directorate.

What the clinical data show

The 2003 Cochrane review on vinpocetine for cognitive impairment and dementia (Szatmari & Whitehouse 2003; PMID 12535455) concluded that the evidence in dementia was inconclusive, with most trials small, short, and methodologically weak. Later reviews of vinpocetine in vascular cognitive impairment have reported small improvements in cognitive test scores and cerebral blood flow at 15–30 mg/day (typically split into three doses), with mechanisms thought to include PDE1 inhibition, sodium-channel modulation, and mild cerebral vasodilation. In healthy adults without cognitive impairment, effects on memory and attention have been small and inconsistent.

Drug interactions and other risks

Vinpocetine has mild antiplatelet activity, so it may add to bleeding risk when combined with warfarin, direct oral anticoagulants, aspirin, NSAIDs, or fish oil at high doses. It is metabolized by CYP3A4 and CYP2C19, so strong inhibitors and inducers of those enzymes can alter blood levels. There are scattered case reports in the FDA Adverse Event Reporting System (FAERS) of agranulocytosis, gastrointestinal upset, and palpitations associated with vinpocetine-containing supplements, although causation is hard to establish from spontaneous reports alone.

What the user should know

Vinpocetine is more like a medication than a typical supplement ingredient. Anyone considering it should treat it that way: avoid in pregnancy or if pregnancy is possible, avoid in people with bleeding disorders or on anticoagulants, and discuss with a clinician before taking it long term. Its narrow clinical role (mainly vascular cognitive impairment in older adults under medical supervision in countries where it is licensed) does not justify routine over-the-counter use by healthy adults seeking memory enhancement.